Martin F. Dietrich

In this discussion, Dr. Martin F. Dietrich, a medical oncologist and assistant professor, dives into the significance of HER2 and MET immunohistochemistry testing for non-small cell lung cancer patients. He outlines the rationale for testing and the challenges oncologists face in implementing these guidelines. The conversation highlights the importance of retesting as patients progress, the potential of novel therapies, and the need for standardized workflows to improve patient outcomes in oncology.